

SUSPECT ADVERSE REACTION REPORT

I. REACTION INFORMATION

1. PATIENT INITIALS (first, last) PRIVACY	1a. COUNTRY GUATEMALA	2. DATE OF BIRTH			2a. AGE 93 Years	3. SEX Male	3a. WEIGHT Unk	4-6 REACTION ONSET			8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION
		Day	Month	Year				Day	Month	Year	
			PRIVACY						Unk		

7 + 13 DESCRIBE REACTION(S) (including relevant tests/lab data)

Event Verbatim [PREFERRED TERM] (Related symptoms if any separated by commas)	Product	Serious	Listed	Reporter Causality	Company Causality
PATIENT PRESENTED COVID-19 DURING TREATMENT [COVID-19]	LYNPARZA	No	No	Not Applicable	Not Related
PATIENT BEGAN TO DECLINE A LOT [Asthenia]	LYNPARZA	No	Yes	Not Applicable	Not Related
DOCTOR FELT THE MEDICATION WAS NOT WORKING FOR THE PATIENT [Drug ineffective]	LYNPARZA	No	No	Related	Not Applicable
PATIENT WAS LIKE GONE [Distractibility]	LYNPARZA	No	No	Related	Related
PATIENT DIDN'T ALWAYS REACT [Hypokinesia]	LYNPARZA	No	No	Not Applicable	Not Related

(Continued on Additional Information Page)

☐ PATIENT DIED
☐ INVOLVED OR PROLONGED INPATIENT HOSPITALISATION
☐ INVOLVED PERSISTENT OR SIGNIFICANT DISABILITY OR INCAPACITY
☐ LIFE THREATENING
☐ CONGENITAL ANOMALY
☐ OTHER

II. SUSPECT DRUG(S) INFORMATION

14. SUSPECT DRUG(S) (include generic name) #1) LYNPARZA (OLAPARIB) Capsule		20. DID REACTION ABATE AFTER STOPPING DRUG? <input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/> NA
15. DAILY DOSE(S) #1) UNK	16. ROUTE(S) OF ADMINISTRATION #1) Oral use	
17. INDICATION(S) FOR USE #1) (Not Coded)		21. DID REACTION REAPPEAR AFTER REINTRODUCTION? <input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> NA
18. THERAPY DATES(from/to) #1) Unknown	19. THERAPY DURATION #1) Unknown	

III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)		
23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.)		
From/To Dates Unknown	Type of History / Notes	Description

IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER AstraZeneca Serban Ghiorgiu 1 Medimmune Way Gaithersburg, Maryland 20878 UNITED STATES Phone: +1 301-398-0000		26. REMARKS World Wide #: GT-ASTRAZENECA-202506CAM016183GT Study ID: PSP-23269 Case References: GT-AstraZeneca-CH-00894638A
	24b. MFR CONTROL NO. 202506CAM016183GT	25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD. NAME AND ADDRESS WITHHELD.
24c. DATE RECEIVED BY MANUFACTURER 18-JUN-2025	24d. REPORT SOURCE <input checked="" type="checkbox"/> STUDY <input type="checkbox"/> LITERATURE <input type="checkbox"/> HEALTH PROFESSIONAL <input type="checkbox"/> OTHER:	
DATE OF THIS REPORT 24-JUN-2025	25a. REPORT TYPE <input checked="" type="checkbox"/> INITIAL <input type="checkbox"/> FOLLOWUP:	

24-Jun-2025 05:48

ADDITIONAL INFORMATION**7+13. DESCRIBE REACTION(S) continued**

Event Verbatim [PREFERRED TERM] (Related symptoms if any separated by commas)	Product	Serious	Listed	Reporter Causality	Company Causality
PATIENT WAS ALWAYS SLEEPY [Somnolence]	LYNPARZA	No	No	Not Applicable	Not Related

Case Description: A solicited report has been received from a consumer in Patient Support Program. The report concerns a male elderly patient (age 93 years).

No medical history was reported.

No concomitant products were reported.

The patient started treatment with Lynparza (olaparib) UNK, Oral use, on an unknown date.

On an unknown date, the patient experienced patient presented covid-19 during treatment (preferred term: COVID-19), patient was always sleepy (preferred term: Somnolence), patient didn't always react (preferred term: Hypokinesia), patient was like gone (preferred term: Distractibility), doctor felt the medication was not working for the patient (preferred term: Drug ineffective) and patient began to decline a lot (preferred term: Asthenia).

The report described lack of effect for Lynparza. The reported term was "doctor felt the medication was not working for the patient" (preferred term: Drug ineffective).

The outcome of the event(s) of patient didn't always react, patient presented covid-19 during treatment, patient was always sleepy and patient was like gone was unknown. At the time of reporting, the event doctor felt the medication was not working for the patient and patient began to decline a lot was ongoing.

The events were considered non-serious.

The reporter did not assess causality for patient began to decline a lot, patient didn't always react, patient presented covid-19 during treatment and patient was always sleepy. The reporter considered that there was a reasonable possibility of a causal relationship between Lynparza and the following event(s): doctor felt the medication was not working for the patient and patient was like gone. The company physician did not consider that there was a reasonable possibility of a causal relationship between Lynparza and the following event(s): patient began to decline a lot, patient didn't always react, patient presented covid-19 during treatment and patient was always sleepy. The company physician considered that there was a reasonable possibility of a causal relationship between Lynparza and the following event(s): patient was like gone.